Evidence map›Paper›PMID 32220861›Full record

SynthesisBMJ evidence-based medicine2021

Improving the transparency of meta-analyses with interactive web applications.

Thomas P Ahern, Richard F MacLehose, Laura Haines, Deirdre P Cronin-Fenton, Per Damkier, Lindsay J Collin, Timothy L Lash

Abstract readMeta-Analysis
In one paragraph

Synthesis in BMJ evidence-based medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. CYP2D6 Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Thomas P AhernDepartments of Surgery and Biochemistry, The Larner College of Medicine at the University of Vermont, Burlington, Vermont, USA thomas.ahern@med.uvm.edu.ORCID 0000-0003-0440-8727
Richard F MacLehoseDivision of Epidemiology & Community Health, University of Minnesota School of Public Health, Minneapolis, Minnesota, USA.
Laura HainesDana Medical Library, The Larner College of Medicine at the University of Vermont, Burlington, VT, USA.
Deirdre P Cronin-FentonDepartment of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.
Per DamkierDepartment of Clinical Biochemistry and Pharmacology, University of Southern Denmark, Odense, Denmark.
Lindsay J CollinDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
Timothy L LashDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.

Funding

Vermont Center on Behavior and HealthP20GM103644 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI HIGGINS, STEPHEN T · 2013 to 2022
$21.3M
New and integrated perspectives on modification of tamoxifen effectivenessR01CA166825 · NCI · EMORY UNIVERSITY · PI LASH, TIMOTHY L. · 2013 to 2017
$2.8M
Improving Reproducibility by Incorporating UncertaintyR01LM013049 · NLM · EMORY UNIVERSITY · PI LASH, TIMOTHY L. · 2019 to 2022
$1.1M
Modification of tamoxifen effectiveness by gene polymorphisms and other drugsR01CA118708 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LASH, TIMOTHY L. · 2006 to 2009
$963k
Biologic and Patient Variation Affecting Breast Cancer Treatment EfficacyF31CA239566 · NCI · EMORY UNIVERSITY · PI COLLIN, LINDSAY JANE · 2019 to 2020
$53k
NCI NIH HHS F31 CA239566NCI NIH HHS R01 CA118708NCI NIH HHS R01 CA166825NIGMS NIH HHS P20 GM103644NLM NIH HHS R01 LM013049
6 · The paper itself

Abstract

Increased transparency in study design and analysis is one proposed solution to the perceived reproducibility crisis facing science. Systematic review and meta-analysis-through which individual studies on a specific association are ascertained, assessed for quality and quantitatively combined-is a critical process for building consensus in medical research. However, the conventional publication model creates static evidence summaries that force the quality assessment criteria and analytical choices of a small number of authors onto all stakeholders, some of whom will have different views on the quality assessment and key features of the analysis. This leads to discordant inferences from meta-analysis results and delayed arrival at consensus. We propose a shift to interactive meta-analysis, through which stakeholders can take control of the evidence synthesis using their own quality criteria and preferred analytic approach-including the option to incorporate prior information on the association in question-to reveal how their summary estimate differs from that reported by the original analysts. We demonstrate this concept using a web-based meta-analysis of the association between genetic variation in a key tamoxifen-metabolising enzyme and breast cancer recurrence in tamoxifen-treated women. We argue that interactive meta-analyses would speed consensus-building to the degree that they reveal invariance of inferences to different study selection and analysis criteria. On the other hand, when inferences are found to differ substantially as a function of these choices, the disparities highlight where future research resources should be invested to resolve lingering sources of disagreement.

Indexed as

Biomedical ResearchSoftwareData Interpretation, StatisticalFemaleHumansReproducibility of ResultsResearch Designbreast tumoursstatistics & research methods

Identifiers

PMID32220861
PMCPMC7530078

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.